以岭药业获信达证券增持评级，推动新药研发

金融界04-30

4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。研报预计以岭药业2024-2026年营收分别为116.83亿元/135.23亿元/157.03亿元，归母净利润分别为19.48亿元/22.45亿元/25.86亿元。研报认为，以岭药业正处于业绩高基数下的短期承压阶段，而公司在2024年一季度报告显示因去年同期高基数及社会库存高企导致市场需求下降，营业收入和归母净利润均有所下滑...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2431393402?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-30 16:24","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2431393402","market":"sh","top_or_hot":-1,"title":"以岭药业获信达证券增持评级，推动新药研发","media":"金融界","content":"<div>\n<p>4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。研报预计以岭药业2024-2026年营收分别为116.83亿元/135.23亿元/157.03亿元，归母净利润分别为19.48亿元/22.45亿元/25.86亿元。研报认为，以岭药业正处于业绩高基数下的短期承压阶段，而公司在2024年一季度报告显示因去年同期高基数及社会库存高企导致市场需求下降，营业收入和归母净利润均有所下滑...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>以岭药业获信达证券增持评级，推动新药研发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n以岭药业获信达证券增持评级，推动新药研发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 16:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。研报预计以岭药业2024-2026年营收分别为116.83亿元/135.23亿元/157.03亿元，归母净利润分别为19.48亿元/22.45亿元/25.86亿元。研报认为，以岭药业正处于业绩高基数下的短期承压阶段，而公司在2024年一季度报告显示因去年同期高基数及社会库存高企导致市场需求下降，营业收入和归母净利润均有所下滑...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"601059","symbol_name":"信达证券","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b","article_id":"2431393402","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301624308b656d8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2431393402","pubTimestamp":1714465466,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。信达证券指出，以岭药业其他专利产品销售保持稳定增长，并且在心脑血管和健康产品研发领域取得进展。展望未来，信达证券看好以岭药业在中药、化生药两大核心板块新药研发所带来的业绩增长潜力。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"601059":"信达证券","002603":"以岭药业"},"translate_title":"Yiling Pharmaceutical received an overweight rating from Cinda Securities to promote the research and development of new drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601059":1,"002603":1},"content_text":"4月30日，以岭药业获信达证券增持评级，近一个月以岭药业获得2份研报关注。研报预计以岭药业2024-2026年营收分别为116.83亿元/135.23亿元/157.03亿元，归母净利润分别为19.48亿元/22.45亿元/25.86亿元。研报认为，以岭药业正处于业绩高基数下的短期承压阶段，而公司在2024年一季度报告显示因去年同期高基数及社会库存高企导致市场需求下降，营业收入和归母净利润均有所下滑。但公司致力于依据战略规划和年度经营计划，继续抓住行业高质量发展契机，强化经营管理水平、提升研发产出效率、优化营销体系以实现稳健发展。信达证券指出，以岭药业其他专利产品销售保持稳定增长，并且在心脑血管和健康产品研发领域取得进展。公司新增了多项国家发明专利和国际专利，上榜中国创新品牌100强。展望未来，信达证券看好以岭药业在中药、化生药两大核心板块新药研发所带来的业绩增长潜力。风险提示：市场及政策风险、药品降价风险、研发创新风险、流动性风险。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431393402"}